(Q33715766)

28 July 2017

6 references

22 March 2019

19 September 2019

2 October 2019

19 November 2019

4 December 2020

3 October 2022

0 references

Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis (English)

1 reference

biomedical investigative technique

28 July 2017

0 references

pulmonary hypertension

4 references

22 March 2019

19 September 2019

2 October 2019

19 November 2019

1 reference

19 September 2019

1 reference

2 October 2019

1 reference

19 November 2019

antihypertensive drug

1 reference

4 December 2020

1 reference

1 reference

Christopher J Ryerson

1

1 reference

28 July 2017

Shalini Nayar

2

1 reference

28 July 2017

John R Swiston

3

1 reference

28 July 2017

Don D Sin

4

1 reference

28 July 2017

language of work or name

1 reference

29 January 2010

7 references

28 July 2017

22 March 2019

19 September 2019

2 October 2019

19 November 2019

4 December 2020

3 October 2022

7 references

28 July 2017

22 March 2019

19 September 2019

2 October 2019

19 November 2019

4 December 2020

3 October 2022

11

1 reference

28 July 2017

page(s)

12

1 reference

Creative Commons Attribution 2.0 Generic

28 July 2017

copyright license

6 references

22 March 2019

19 September 2019

2 October 2019

19 November 2019

4 December 2020

on focus list of Wikimedia project

3 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1465-9921-11-12

0 references

cites work

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Sildenafil citrate therapy for pulmonary arterial hypertension

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Sitaxsentan therapy for pulmonary arterial hypertension

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Inhaled iloprost for severe pulmonary hypertension

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835653

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

30 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-11-12

Bosentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

12 December 2020

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

12 December 2020

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

12 December 2020

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

1 reference

12 December 2020

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

12 December 2020

Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan

1 reference

12 December 2020

Identifiers

DOI

10.1186/1465-9921-11-12

1 reference

Dimensions Publication ID

28 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1465-9921-11-12

9 September 2019

1 reference

28 July 2017

1 reference